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Functional Roles of Src and Fgr in Ovarian Carcinoma
Hye-Sun Kim1,8, Hee Dong Han1,5, Guillermo N. Armaiz-Pena1, Rebecca L. Stone1, Eun Ji Nam1,9,
Jeong-Won Lee1,10, Mian M. K. Shahzad1,7, Alpa M. Nick1, Sun Joo Lee1,11, Ju-Won Roh1,12,
Masato Nishimura1, Lingegowda S. Mangala1,6, Justin Bottsford-Miller1, Gary E. Gallick2,
Gabriel Lopez-Berestein3,4,5, and Anil K. Sood1,4,5
Abstract
Purpose: Src is an attractive target because it is overexpressed in a number of malignancies, including
ovarian cancer. However, the effect of Src silencing on other Src family kinases (SFKs) is not known. We
hypothesized that other SFK members could compensate for the lack of Src activity.
Experimental Design: Cell viability after either Src or Fgr silencing was examined in ovarian cancer cell
lines by MTT assay. Expression of SFKs after Src silencing in ovarian cancer cells was examined by real-time
reverse transcriptase (RT)-PCR. Therapeutic effect of in vivo Src and/or Fgr silencing was examined using
siRNA incorporated into chitosan nanoparticles (siRNA/CH-NP). Microvessel density, cell proliferation,
and apoptosis markers were determined by immunohistochemical staining in ovarian tumor tissues.
Results: Src silencing enhanced cytotoxicity of docetaxel in both SKOV3ip1 andHeyA8 cells. In addition,
Src silencing using siRNA/CH-NP in combination with docetaxel resulted in significant inhibition of tumor
growth compared with control siRNA/CH-NP (81.8% reduction in SKOV3ip1, P¼ 0.017; 84.3% reduction
in HeyA8, P < 0.005). These effects were mediated by decreased tumor cell proliferation and angiogenesis,
and increased tumor cell apoptosis. Next, we assessed the effects of Src silencing on other SFK members in
ovarian cancer cell lines. Src silencing resulted in significantly increased Fgr levels. Dual Src and Fgr silencing
in vitro resulted in increased apoptosis that wasmediated by increased caspase and AKT activity. In addition,
dual silencing of Src and Fgr in vivo using siRNA/CH-NP resulted in the greatest reduction in tumor growth
compared with silencing of either Src or Fgr alone in the HeyA8 model (68.8%, P < 0.05).
Conclusions: This study demonstrates that, in addition to Src, Fgr plays a biologically significant role in
ovarian cancer growth and might represent an important target. Clin Cancer Res; 17(7); 1713–21. 2011
AACR.
Introduction
Ovarian cancer is the fifth leading cause of cancer death
in women in the United States with an estimated 21,550
new cases diagnosed in 2009, and 14,600 deaths (1). The
high mortality for ovarian cancer has changed little despite
improvements in surgical and chemotherapeutic
approaches. The main reasons for high mortality rates
associated with ovarian cancer are advanced disease at
the time of diagnosis and high recurrence rates after initial
treatment (2). Therefore, new therapeutic approaches are
needed to improve the outcome of women with ovarian
cancer.
Src family kinases (SFKs) comprise a subclass of mem-
brane-associated nonreceptor tyrosine kinases that are
involved in a variety of cellular processes important for
cancer growth and progression, such as cell division, moti-
lity, adhesion, angiogenesis, and survival (3,4). Several of
the SFKs have been shown to be upregulated in cancer
and promote progression and metastasis. Among SFKs, Src
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has arguably been the best characterized and most often
implicated in cancer. Furthermore, Src is a particularly
attractive target because it is overexpressed in a number
of malignancies, including ovarian cancer (5). Even though
Src is the most widely studied SFK, there remains a void in
understanding how other SFKs might relate to Src-
mediated functions and potentially contribute to redun-
dant pathways.
Emerging data suggest that SFKs play key roles in tumor
growth and progression. Among these, Fgr localizes to
plasma membrane ruffles, and functions as a negative
regulator of cell migration and adhesion triggered by the
beta-2 integrin signal transduction pathway. Moreover, Fgr
is overexpressed in hematopoietic cells and associated with
adhesion and migration of granulocytes (6–10). Recently,
Fgr overexpression was found to be associated with aggres-
sive tumor features, and shorter overall survival among
patients with leukemia (11), lymphoma (12), or glioblas-
toma multiforme (13). However, the role of Fgr in cancer
treatment is not known.
Here, we sought to determine whether other SFK mem-
bers could compensate for the lack of Src activity. Our
findings demonstrate that Src and Fgr play key roles in
ovarian cancer growth and progression. Moreover, dual
silencing of Src and Fgr results in increased apoptosis and
effective antitumor activity.
Materials and Methods
Cell lines
The ovarian cancer cell lines, HeyA8 and SKOV3ip1,
were maintained and propagated in RPMI 1640 supple-
mented with 15% FBS and 0.1% gentamicin sulfate
(Gemini Bioproducts). The taxane-resistant HeyA8-
MDR cells were a generous gift from Dr. Isaiah J. Fidler,
Department of Cancer Biology, University of Texas M. D.
Anderson Cancer Center, Houston, TX. They were main-
tained in RPMI 1640 supplemented with 15% FBS
and 300 ng/mL paclitaxel. All in vitro and in vivo experi-
ments were conducted when cells were 70% to 80%
confluent.
SiRNA
Target sequences for Src (5’-GGGCGAACCACCUGAA-
CAA-3’), Fgr (50 0-GACAUGGGCGGCUACUACA-3’), and
control (5’-UUCUCCGAACGUGUCACGU-3’) were pur-
chased from Sigma Genosys.
Western blot
Preparation of cell and tumor tissue lysates has been
previously described (14). Protein concentrations were
determined using a BCA Protein Assay Reagent Kit (Pierce
Biotech.) and aliquots of 20 mg protein were subjected to
gel electrophoresis on 7.5% or 10% SDS-PAGE gels. Trans-
fer to membranes and immunoblotting were performed as
described previously (14).
Cell viability assay
Cells were plated on 96-well plates in triplicate and
incubated for 24 hours at 37C and 5% CO2. After incuba-
tion, cells were washed, serum and antibiotic-free medium
added and treated with control, Src, or Fgr siRNA. After 6
hours, cells were washed and incubated in serum-contain-
ing medium overnight. Afterwards, cells were washed and
either regular or docetaxel containing mediumwere added.
After 72 hours, cell viability was determined by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay (15).
Real-time RT-PCR
Relative expression of SFKs (Src, Fgr, Fyn, Hck, Lyn, and
Yes) mRNA after Src silencing was determined by real-time
quantitative PCR analysis of total RNA isolated from
HeyA8 using the RNeasy Mini Kit (Qiagen) following
the manufacturer’s protocol. Fold change for relative
expression was calculated using the 2DDCT method, as
previously described (16).
Cell apoptosis
Relative percentage of apoptotic cells was assessed by
propidium iodide (PI) staining, as previously described
(15). Briefly, SKOV3ip1 cells (106 cells/mL) were pelleted
and washed twice in PBS and resuspended in PBS contain-
ing PI (5 mL per 105 cells). Samples were incubated in the
dark for 15 minutes at room temperature before being
analyzed by flow cytometry.
Cell migration and invasion assays
Cell migration and invasion assays have been previously
described (17). In brief, cells were treated with either
control, Fgr, Src, or combination of Fgr and Src siRNA
for 24 hours. Then, cells were re-suspended in serum-free
medium (1  106 cells/mL), and 1 mL added to gelatin-
coated inserts. The inserts were then transferred to wells
filled with serum-containing media. Cells were allowed to
migrate for 6 hours at 37C. Cells that had migrated into
the bottom wells were collected, fixed, stained, and
counted by light microscopy. Cells were counted in 10
random fields (200 final magnification) and the average
number of cells determined.
Translational Relevance
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are involved in a variety of cellular processes important
for cancer growth. Even though Src is a key mediator of
malignant cell function, there remains a void in under-
standing how other SFKs might relate to Src-mediated
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For invasion assays, cells were treated with control, Fgr,
Src, or combination of Fgr and Src siRNA for 36 hours.
Then, cells were resuspended in serum-free medium
(5  105 cells/mL), and 1 mL added to inserts coated with
a defined matrix consisting of human laminin, type IV
collagen, and gelatin (17). Inserts were then transferred to
wells filled with serum-containing media. Cells were then
allowed to invade for 24 hours at 37C. Cells that had
migrated into the bottom wells were collected, fixed,
stained, and counted by light microscopy. Cells were
counted in 10 random fields (200 final magnification)
and the average number of cells determined.
Preparation of siRNA incorporated chitosan
nanoparticles (siRNA/CH-NP)
SiRNA/CH-NP was prepared based on ionic gelation of
anionic tripolyphosphate (TPP) and siRNA, as previously
described (18, 19). In brief, predetermined TPP (0.25%
w/v) and siRNA (1 mg/mL) were added into a chitosan
solution. After constant stirring at room temperature,
siRNA/CH-NP was formed. The siRNA/CH-NP was col-
lected by centrifugation after an incubation of 40 minutes
at 4C. The pellet was washed 3 times to remove unbound
chemicals or siRNA. The siRNA/CH-NP was stored at 4C
until needed.
In vivo tumor model and tissue processing
Female athymic nude mice (NCr-nu) were purchased
from the National Cancer Institute-Frederick Cancer
Research and Development Center, Frederick, MD and
housed in specific pathogen-free conditions. They were
cared for in accordance with guidelines set forth by the
American Association for Accreditation of Laboratory Ani-
mal Care and the USPHS Policy onHuman Care andUse of
Laboratory Animals, and all studies were approved and
supervised by the M. D. Anderson Cancer Center Institu-
tional Animal Care and Use Committee. For in vivo experi-
ments, ovarian cancer cells were harvested with trypsin-
EDTA (Life Technologies) and centrifuged at 1,200 rpm for
5 minutes at 4C, then washed twice with PBS, and recon-
stituted in the appropriate volume of HBSS (Life Technol-
ogies) for a final concentration of 2.5 105 cells/mouse for
HeyA8 or 1  106 cells/mouse for SKOV3ip1 and HeyA8-
MDR. Tumor was established by i.p. injections.
To assess tumor growth, treatment began 1 week after
injection of tumor cells. Mice were randomly divided into 4
groups (n ¼ 10 mice per group) for the Src silencing
experiment: (a) control siRNA/CH-NP þ PBS, (b) control
siRNA/CH-NP þ docetaxel, (c) Src siRNA/CH-NP þ PBS,
and (d) Src siRNA/CH-NP þ docetaxel. For dual silencing
of Src and Fgr, mice were also randomly divided into 4
groups (n¼ 10mice per group): (a) control siRNA/CH-NP,
(b) Src siRNA/CH-NP, (c) Fgr siRNA/CH-NP, and (d) Src
and Fgr siRNA/CH-NP. Each siRNA/CH-NP was injected
intravenously twice a week at a dose of 150 mg/kg body
weight and docetaxel was injected into the peritoneal cavity
once a week at a dose of 2mg/kg (HeyA8 andHeyA8-MDR)
or 1.4 mg/kg (SKOV3ip1). Mice were sacrificed after they
became moribund (typically 4 to 5 weeks depending on
tumor cell type). Tumor weight, number of tumor nodules,
and distribution of tumors were recorded. Tumor tissue
was snap-frozen for protein analysis or immersed in opti-
mum cutting temperature (OCT) medium for frozen slide
preparations. Tumor specimens were also fixed in formalin
for paraffin slide preparation.
Immunohistochemical staining
Immunohistochemical analysis for CD31 and Ki67 was
performed as previously described (20). To quantify micro-
vessel density (MVD), the number of blood vessels staining
positive for CD31 was recorded in 5 random fields at200
magnification for each sample. For Ki67, the number of
positive cells and the total number of cells were counted in
5 random fields at 200 magnification for each sample.
Terminal deoxynucleotidyl transferase-mediated deoxyur-
idine triphosphate nick-end labeling (TUNEL) stain was
performed on frozen tissue using Promega Kit (Promega)
and cells were countered in 5 random fields at 200
magnification (20).
Statistical analyses
Differences in continuous variables were analyzed using
the Student’s t-test or ANOVA as appropriate. For values
that were not normally distributed, the Mann–Whitney
rank sum test was used. A P value of <0.05 was considered
statistically significant. The statistical package for the Social
Sciences (SPSS, Inc.) was used for all statistical analyses.
Results
In vitro Src silencing
Before testing the in vivo biological effect of Src gene
silencing, we first tested the in vitro effects on SKOV3ip1
and HeyA8 cells. Both cell lines were harvested at time
points ranging from 24 to 96 hours after transfection with
Src siRNA and the expression of total Src was determined by
Western blot (Fig. 1A). The protein expression of Src
reached maximum downregulation between 48 and 72
hours in the SKOV3ip1 and HeyA8 cells (Fig. 1A). As
expected, Src silencing resulted in decreased phosphoryla-
tion of downstream proteins such as FAK (Supplementary
Fig. S1). We have previously reported that a Src-targeted
small molecule inhibitor can sensitize ovarian cancer cells
to taxanes (5). Because small molecule inhibitors can have
nonspecific effects, we examined the effects of Src gene
silencing on cell viability. Src silencing enhanced the cyto-
toxicity of docetaxel in both SKOV3ip1 and HeyA8 cells
across a range of concentrations. In both cell lines, Src
silencing resulted in lower cell viability compared with the
no treatment and control siRNA groups (P < 0.05; Fig. 1B).
Therapeutic efficacy of Src silencing
Based on prior in vitro data, we next assessed in vivo
therapeutic efficacy of Src silencing. For systemic delivery of
siRNA, we have recently developed a highly efficient
method using chitosan nanoparticles (19). Seven days after
Functional Roles of Src and Fgr in Ovarian Carcinoma
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i.p. injection of tumor cells, mice were randomly allocated
to 1 of 4 treatment groups. Mice were sacrificed when
animals in any group became moribund. As expected,
tumor growth was significantly reduced in the control
siRNA/CH-NP þ docetaxel group (Fig. 2A). Src siRNA/
CH-NPþ PBS also resulted in significant growth inhibition
compared with control siRNA/CH-NP þ PBS (52.8% and
51.8% reduction in SKOV3ip1; 57.9% and 38.5% reduc-
tion in HeyA8; Fig. 2A and B). Combination of Src siRNA/
CH-NP þ docetaxel resulted in the greatest tumor reduc-
tion compared with control siRNA/CH-NP þ PBS (81.8%
reduction in SKOV3ip1, P ¼ 0.017; 84.3% reduction in
HeyA8, P < 0.005; Fig. 2A and B).
Given the suspected role for Src in resistance to che-
motherapy, we also examined the effects of Src gene silen-
cing in the taxane-resistant HeyA8-MDR model (Fig. 2C).
Src siRNA/CH-NP þ PBS reduced tumor growth by 71.2%
compared with control siRNA/CH-NPþ PBS. Additionally,
combination treatment of Src siRNA/CH-NP with doce-
taxel resulted in 92.3% reduction of tumor growth com-
pared with control siRNA/CH-NP þ PBS (P ¼ 0.02;
Fig. 2C).
To determine potential mechanisms responsible for the
therapeutic effects of Src silencing and docetaxel, we exam-
ined tumor cell proliferation (Ki67), tumor associated
MVD (CD31 staining), and tumor cell apoptosis (TUNEL)
(Fig. 2D and Supplementary Fig. S2). Tumor cell prolifera-
tion was significantly reduced in the Src siRNA/CH-NP
þ docetaxel group compared with the control siRNA/CH-
NP þ PBS group (25% reduction, P < 0.001; Fig. 2D).
Similar effects were observed in the HeyA8 and HeyA8-
MDR models (Supplementary Fig. S2). Additionally, MVD
was significantly reduced in both SKOV3ip1 and HeyA8
models (Fig. 2D and Supplementary Fig. S2A); however,
the greatest reduction was noted in the combination group
(75% and 60% reduction in the SKOV3ip1 and HeyA8
models, respectively, P < 0.001). In the HeyA8-MDR
model, there was no significant reduction with control
siRNA/CH-NPþ PBS or control siRNA/CH-NPþ docetaxel
(P ¼ 0.17), however, combination treatment resulted in
significantly decreased MVD compared with control
siRNA/CH-NP þ PBS (42.9%, P < 0.001; Supplementary
Fig. S2B). Notably, combined treatment of Src siRNA/CH-
NP þ docetaxel resulted in a significant increase in tumor
cell apoptosis compared with control siRNA/CH-NPþ PBS
(P < 0.001 for both SKOV3ip1 and HeyA8, P ¼ 0.02 for
HeyA8-MDR; Fig. 2D and Supplementary Fig. S2).
Src silencing increases Fgr levels
We next considered whether other SFK levels are affected
by Src silencing. Therefore, we analyzed changes in mRNA
expression levels of other SFK members (Src, Fgr, Fyn, Hck,
Lyn, and Yes) in response to Src silencing (Fig. 3A). After Src
silencing, Fgr mRNA levels were increased by 2-fold com-
pared with controls at 96 hours. In addition, we observed
similar effects of Src silencing on Fgr protein levels
Figure 1. In vitro effect of Src
silencing by Src siRNA. A,
Western blot analysis of Src in
SKOV3ip1 and HeyA8 cells after
transfection with Src siRNA for 24,
48, 72, and 96 hours. Protein
levels were quantified by
densitometry and expression is
shown as% expression of Src. B,
Cell viability after Src siRNA
transfection combined with
docetaxel on SKOV3ip1 and
HeyA8 cells. Error bar represent
SEM.
Kim et al.
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(Fig. 3B). Because Fgr mRNA levels were significantly
increased after Src silencing, we considered whether Fgr
might play a complementary role to Src. On the basis of
these results, we next examined the in vitro and in vivo
effects of simultaneously silencing Src and Fgr.
For testing the in vitro effects of Fgr silencing, a siRNA
sequence was designed that reduced Fgr expression by
>90% after 72 hours compared with control siRNA
(Fig. 3C). Subsequently, we sought to determine whether
Fgr silencing could sensitize ovarian cancer cells to che-
motherapy. Based on cell viability assays, Fgr silencing
enhanced the cytotoxic effect combined with docetaxel
(Fig. 3D). Subsequently, we assessed whether dual Src
and Fgr silencing could promote tumor cell apoptosis.
Although Src or Fgr silencing individually did not result
in increased tumor cell apoptosis, dual silencing resulted in
significantly increased tumor cell apoptosis by more than
2-fold compared with all other groups (P < 0.01; Fig. 4A
and Supplementary Fig. S3). To identify potential pathways
that could be responsible for the increased rate of apoptosis
after dual Src and Fgr silencing, we analyzed the activity of
several known pro-apoptotic proteins by Western blot
(Fig. 4B). Caspase 3, 8, and 9 levels were increased after
dual Src and Fgr silencing. Moreover, AKT activity was also
significantly increased after dual Src and Fgr silencing
(Fig. 4B), suggesting that the increase in tumor cell apop-
totic rate after dual silencing might be mediated by the
activation of AKT and caspases. In addition, we tested
effects of small molecule inhibitors such as PP2 and dasa-
tinib on Src activity and Fgr levels. Treatment of ovarian
cancer cells with these inhibitors also resulted in increased
Fgr levels (Supplementary Fig. S4). These data indicate that
dual Src and Fgr silencing results in increased apoptosis
through caspase activation. We also examined the effects of
dual Src and Fgr silencing on cancer cell migration and
invasion. Dual silencing resulted in significantly decreased
Figure 2. Therapeutic efficacy of
Src siRNA/CH-NP. Mice injected
with A, SKOV3ip1, B, HeyA8, or C,
HeyA8-MDR cells were initiated in
control siRNA/CH-NP, Src siRNA/
CH-NP twice a week, docetaxel
once a week, and combination of
Src siRNA/CH-NP and docetaxel.
Treatments were started 1 week
after tumor cell injection and
siRNA/CH-NP injected twice
weekly at a dose of 150 mg/kg
body weight and docetaxel 35 mg
for SKOV3ip1 and 50 mg for HeyA8
tumor model. All of the animals
were sacrificed when animals in
any group appeared moribund.
Statistical analysis for tumor
weights was done by Student's
t-test, P < 0.05. D, In vivo effects
of Src silencing on tumor cell
proliferation, angiogenesis, and
apoptosis. Immunohistochemical
stains for cell proliferation and
angiogenesis, and TUNEL stain
for apoptosis were performed on
SKOV3ip1-bearing mice.
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cell migration and invasion, however, these effects were
similar to silencing each gene individually (Supplementary
Fig. S5).
On the basis of the in vitro findings noted above, we next
examined the in vivo effects of dual Src and Fgr silencing
using Src siRNA/CH-NP and Fgr siRNA/CH-NP. Mice were
Figure 3. A, Effect of Src silencing
on the SFKs in ovarian cancer cell
line. Real-time RT-PCR was
performed in HeyA8 cells to
evaluate the expression level of
mRNA of SFKs after Src silencing
(96 hours). B, Western Blot
analysis demonstrating the effect
of Src silencing on Fgr protein
levels. C, In vitro effects of Fgr
silencing by Fgr siRNA was
observed by Western blot in
HeyA8 cells. D, Effect of Fgr
silencing in combination with
docetaxel on ovarian cancer cell
viability. Error bar represent SEM.
Figure 4. Effect of Src and Fgr
silencing on SKOV3ip1. A,
Apoptosis was measured as the
percentage of PI-positive cells.
Error bar represent SEM, P < 0.05.
B, After dual silencing of Src and
Fgr, SKOV3ip1 lysate was
analyzed by western blot for AKT
and caspase 3, 8, and 9 activity.
Kim et al.
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injected i.p. with HeyA8 ovarian cancer cells and randomly
divided into the following treatment groups 7 days after
injection (n ¼ 10 mice per group): control siRNA/CH-NP,
Src siRNA/CH-NP, Fgr siRNA/CH-NP or Src/Fgr siRNA/
CH-NP. Both Src and Fgr siRNA/CH-NP inhibited tumor
growth compared with the control siRNA/CH-NP group
(41.9% and 40.5%, respectively; Fig. 5A). Moreover, dual
Src and Fgr silencing resulted in the greatest inhibition in
tumor growth compared with control siRNA/CH-NP
(68.8% reduction, P < 0.005; Fig. 5A).
To examine potential mechanisms responsible for the
decrease in tumor growth after dual Src and Fgr silencing,
we examined tumor cell proliferation, MVD and apoptosis
(Fig. 5B). Tumor cell proliferation was significantly
reduced in the dual Src and Fgr silencing group compared
with the control group (P < 0.001). In addition, tumor
associated MVD was significantly decreased (P < 0.001),
suggesting that dual Src and Fgr silencing might decrease
angiogenesis. Dual Src and Fgr silencing also resulted in a
significant increase in tumor cell apoptosis compared with
the control group (P < 0.001; Fig. 5B).
Discussion
The key findings from this study are that Fgr levels
increase significantly after Src silencing and dual Src and
Fgr silencing is effective in reducingovarian cancer growth in
vivo. These effects were achieved, in part, through decreased
tumor cell proliferation and angiogenesis and increased
tumor cell apoptosis thatwasmediatedby increased caspase
and AKT activity. The in vivo effects of Src silencing were
more pronounced compared to in vitro effects, which is not
surprising given the direct (on tumor cells) and indirect
(e.g., effects of reduced angiogenesis) effects. These findings
Figure 5. In vivo effects of Src and
Fgr silencing. A, Mean tumor
weights with treatment of Src or
Fgr siRNA/CH-NP alone or
combination. Mice injected with
HeyA8 cells were treated with
control siRNA/CH-NP, Src siRNA/
CH-NP, Fgr siRNA/CH-NP, or
combined Src and Fgr siRNA/CH-
NP twice a week. B,
Immunohistochemical stains for
cell proliferation and
angiogenesis, and TUNEL stain
for apoptosis were performed on
HeyA8 tumors. Error bars
represent SEM, P < 0.05.
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suggest that, in addition to targeting Src, Fgrmight represent
an important target in ovarian cancer.
SFKs are a group of membrane-associated nonreceptor
tyrosine kinases that are involved in a variety of cellular
functions including cell proliferation, invasion, migration,
and apoptosis (4). Src has been found to be overexpressed
in a majority of late stage human ovarian cancers (21, 22)
and to promote survival and resistance against chemother-
apy (23). In this study, we demonstrate that Src silencing
inhibited tumor growth compared to controls. The addi-
tion of docetaxel further enhanced inhibition of tumor
growth compared to controls, even in chemo-resistant
models. However, despite the known role of Src in tumor
growth and angiogenesis (5, 23–25), Src inhibitors have
only had modest success (5, 26) suggesting the presence of
compensatory factors. Among these, we found that Fgr
levels were significantly increased after Src silencing. Fgr
is amember of SFKs,which plays a role in cellmigration and
adhesion triggered by the beta-2 integrin signal transduc-
tion pathway in monocytes. Fgr has been known to be
overexpressed in hematopoietic cells, and is associated with
granulocyte adhesion andmigration (6–10).However, Fgr’s
role in cancer cells has not been sufficiently studied. Some
studies suggest that Fgr might play a complementary role to
Src and represent a potential therapeutic target (11, 27).Our
findings extend previous knowledge by demonstrating that
Fgr levels are significantly increased after Src silencing in
ovarian cancer cells. Moreover, this increase in Fgr might
compensate for some of Src’s functions in cancer cells
because gene silencing of both kinases compromised cell
survival to a greater extent. It is possible that such increases
in Fgr might limit the efficacy of Src targeted drugs.
Although a number of important targets in tumor and
endothelial cells have been identified, many of these are
difficult to target with small molecule inhibitors or mono-
clonal antibodies. This limitation prompted us to consider
RNA interference as a therapeutic modality, which holds
great potential for cancer therapy. We have recently devel-
oped chitosan nanoparticles that allow efficient systemic
delivery of siRNA into orthotopic tumors (18, 19). Chit-
osan is highly desirable for biological applications due to
properties such as low immunogenicity and low toxicity
(28–30).
Here, we demonstrate that dual Src and Fgr silencing
is an effective approach for treatment of ovarian carcinoma
in animal models. Dual Src and Fgr silencing further
decreased tumor MVD (angiogenesis), cell survival
(increased apoptosis), and tumor growth. In addition,
these effects might be mediated by increased caspase and
AKT activity. Such combinations warrant further develop-
ment in ovarian and other cancers.
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